-
GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week
ATLANTA, GA – January 6, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company advancing innovative immunotherapies and vaccines for cancer and…
-
GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering
Atlanta, GA, December 19, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,…
-
GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVA
EMA Concurrence Enables Acceleration Toward Phase 3 Initiation and Represents a Major Milestone on GeoVax’s Path to Commercialization ATLANTA, GA – December 18,…
-
GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 Vaccine
Animal Models Show Full Protection Against Omicron Variant Despite Absence of Neutralizing Antibodies, Highlighting Critical Importance of T-cell Immunity for Next-generation COVID-19 Vaccines…
-
GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026
Milestone Advances Clinical Readiness and Reinforces Urgent U.S. Need for Domestic MVA Vaccine Capacity ATLANTA, GA – December 17, 2025 – GeoVax Labs, Inc.…
-
GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine Design
Patent Strengthens GeoVax’s Multi-Antigen Vaccine Platform Designed to Deliver Broader, Longer-Lasting Protection and Support Future Pandemic Preparedness ATLANTA, GA – December 16, 2025…
-
GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients
DSMB Ends Comparator Arm; Trial Proceeds Exclusively With GEO-CM04S1 Following mRNA Vaccine’s Failure to Meet Primary Endpoint Phase 2 Data Reinforce GEO-CM04S1 as…
-
GeoVax Addresses Identification of New Mpox Variant
Continued Mpox Evolution Underscores Dependence on a Single Global Supplier, Reinforcing the Critical Importance of GeoVax’s Accelerated GEO-MVA Program Atlanta, GA – December…
-
GeoVax Announces Addition of Renowned Global Experts to its Scientific Advisory Board
Newly Appointed Members Include Leaders in Vaccine Immunology, T-Cell Science, and Clinical Research Atlanta, GA -December 10, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX),…
-
GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin® Gene Therapy
Patent Protects Novel Application of Gedeptin Therapy Across Multiple Solid Tumor Types; Supports Expansion of Gedeptin Product Platform ATLANTA, GA – December 9,…
-
GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin® in Recurrent Head & Neck Cancer
Phase 1/2 trial confirms safety with repeated dosing supporting further development in early-stage disease and combination treatment settings ATLANTA, GA – December 8,…
-
GeoVax to Present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference
ATLANTA, GA, November 24, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced…